The changing patterns of antimicrobial resistance in Neisseria gonorrhoeae have been reviewed regularly since the introduction of antimicrobial therapy in the 1930s. At present, ceftriaxone, fluoroquinolones, and spectinomycin have remained efficient as single-dose treatment of gonorrhea worldwide. To ensure that limited resources can be used in the best possible way, continuous surveillance of gonococcal resistance to antimicrobials is needed.